Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Funding Component of 21st Century Cures May Get White House Boost

Executive Summary

Vice President’s Cancer Moonshot project could provide final thrust for '21st Century Cures' bill in the lame duck Congressional session after election.

You may also be interested in...



The Unlikely Savior Of 21st Century Cures: Donald Trump

The 21st Century Cures bill made it through the US Congress in 2016 after all; advocates can thank the unexpected presidential victory of Donald Trump for helping to make that happen.

The Unlikely Savior Of ‘21st Century Cures’ Is Donald Trump

The ‘21st Century Cures’ bill made it through the US Congress in 2016 after all; advocates can thank the unexpected presidential victory of Donald Trump for helping make that happen.

Regenerative Medicine In Cures: Conditional Approval Dropped In Lieu Of ‘Breakthrough’-Style Approach

Push to open up new US pathway for regenerative medicine helped the 21st Century Cures bill make it to the finish line in the lame duck Congress – but only after the proposal has been dramatically revised to fit into the established BLA pathway.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel